Professor Wang Feng: The Department of Nuclear Medicine and Urology work side by side, and radioligand therapy has a bright future in prostate cancer.

The diagnosis and treatment of prostate cancer has entered the era of precision treatment.
The development of nuclear medicine has promoted the continuous development of precision treatment of prostate cancer
.

In the 2021 ASCO conference, the results of radioligand therapy (RLT) are exciting
.

During the "2021 Novartis Urinary Tumor Day (NUTD)-Sharing the Kidney Potential and Enjoying New Life" conference, Yimaitong was fortunate to invite Professor Wang Feng, Director of the Nuclear Medicine Department of Nanjing First Hospital, to share radioligand therapy in prostate cancer The broad application prospects
.

Expert Profile Prof.
Feng Wang, Director of the Department of Nuclear Medicine, School of Imaging, Nanjing Medical University, Master of Medicine/Ph.
D.
Supervisor, Director of the Department of Nuclear Medicine, Nanjing First Hospital, Chairman of the 2019 International Conference on Radiopharmaceuticals and Therapy Chairman of the World Society for Radiopharmaceuticals and Targeted Therapy (WARMTH Board Member )Deputy leader of the radiopharmaceutical group of the Chinese Medical Association Nuclear Medicine Branch Chairman of the Nuclear Medicine Branch of the Jiangsu Medical Association Vice Chairman of the Nuclear Medicine Branch of the Jiangsu Medical Association Mechanism innovation of the chairperson, unique precision therapy.
The principle of radionuclide treatment of tumors is to use carriers or other technical means to deliver nuclide drugs to tumor lesions, and then radionuclides release a large amount of energy to kill tumor cells and tissues within range
.

Professor Feng Wang introduced that the principle of radioligand therapy is to use a high-affinity targeting ligand—Prostate Specific Membrane Antigen (PSMA) to direct the radionuclide that emits β or α rays to the tumor cell surface receptors, β or α rays.
Break the tumor DNA structure, and then kill the tumor
.

PSMA is also called glutamate carboxypeptidase II.
It is a hydrolase.
Radioligand therapy utilizes the efficient combination of enzyme and substrate to effectively kill tumor cells..

At the same time, radioligand therapy is a small molecule compound that has a faster clearance rate in the blood, fewer side effects, and has the characteristics of simplicity, safety, high response rate and fewer adverse reactions
.

In addition, Professor Wang Feng also mentioned that radioligand therapy has endocytosis.
Tumor cells have endocytosis for radionuclide-labeled inhibitors, which can irradiate tumor cells in cycles and have a better curative effect
.

The benefits are extraordinary and the clinical treatment prospects are broad.
At the ASCO conference in 2021, the study of the efficacy of 177Lu-PSMA-617 combined with standard treatment compared with standard treatment for metastatic castration-resistant prostate cancer (mCRPC) was evaluated-the VISION study, with LBA The research results are published in the form of an abstract
.

The results showed that the median imaging progression-free survival (rPFS) and overall survival (OS) of the 177Lu-PSMA-617 group were significantly improved
.

Professor Wang Feng said that this is an exciting study
.

The VISION research originated at Heidelberg University, and then it quickly transformed from basic research to clinical research, and obtained the best image of the year at the North American Radiology Annual Conference
.

In real-world reports, some patients have achieved complete remission of their lesions.
Therefore, the VISION study has a broad application prospect in the treatment of prostate cancer
.

Professor Wang Feng also mentioned that with the advancement of medical technology, there are various treatment methods for prostate cancer.
Radioligand therapy can be combined with other treatment methods to have a synergistic effect and play the role of "1+1>2"
.

Cross-disciplinary cooperation to overcome prostate cancer.
Talking about the role of nuclear medicine in the diagnosis and treatment of prostate cancer, Professor Wang Feng emphasized that whether it is the development of traditional nuclear medicine or modern nuclear medicine, it has always been fighting side by side with urology
.

First of all, prostate cancer is prone to bone metastasis.
The bone imaging technology of the nuclear medicine department can detect the metastasis as soon as possible.

.

Secondly, from the perspective of prostate cancer bone metastasis treatment, prostate cancer radioactive seed implantation, 186/188Re, and zoledronic acid are all inseparable from the development of nuclear medicine
.

In recent years, the related research progress of 177Lu-PSMA-617 and radium-223 have indicated that the nuclear medicine department plays an important role in the diagnosis and treatment of prostate cancer
.

From the detection of prostate cancer tumor markers, to diagnosis and treatment, to the development of precision medicine, nuclear medicine and urology have always complemented each other, working side by side, and jointly bringing survival benefits to prostate cancer patients
.

Experts’ message In order to make prostate cancer patients get more accurate diagnosis and more effective treatment, the nuclear medicine department has always "stand together" with the urology department, so that the survival period and quality of life of the patients have been significantly improved
.

The dazzling results of the VISION study at the ASCO conference this year, we see that radioligand therapy can significantly improve patients' rPFS and OS, and also make us confident in the prognosis of prostate cancer
.

Note: *The radioligand therapy (177Lu-PSMA-617) has not been approved for prostate cancer indications.
The interpretation of the conference research data is only for the reference of professional medical professionals!